Clinical and immunologic characteristics of nonhematologic autoimmune disorders in chronic lymphocytic leukemia
Arguello-Tomas, Miguel (Institut de Recerca Sant Pau)
Lynton-Pons, Elionor (Institut de Recerca Sant Pau)
Albiol, Nil (Hospital Clínic i Provincial de Barcelona)
López Ferrer, Anna (Universitat Autònoma de Barcelona. Departament de Medicina)
Sierra, Jorge (Universitat Autònoma de Barcelona. Departament de Medicina)
Moga, Esther (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Moreno, Carol (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))

Fecha:	2025
Resumen:	Background: Autoimmune disorders (AIDs) are frequent in patients with chronic lymphocytic leukemia (CLL). There is little information on the clinical characteristics and pathogenesis of nonhematologic AIDs in patients with CLL, although both entities present immunologic alterations in their clinical onset. Methods: This single-center series included 907 patients with CLL who had a median follow-up of 6. 6 years (range, 0. 1-36. 4 years). Results: In total, 156 patients developed an AID, including 99 patients (10. 9%) with nonhematologic AIDs, 46 (5. 1%) with autoimmune cytopenia (AIC), and 11 (1. 2%) with both; autoimmune hypothyroidism and psoriasis were the most frequent AIDs. Patients with nonhematologic AIDs had low-risk genetic features and were related to a better time to first treatment than patients with AIC (13. 8 vs. 5. 5 years; p <. 001). Patients with both CLL and psoriasis had the lowest risk of progression. The authors performed a T-cell/natural killer-cell and cytokine assessment among patients who had CLL with and without psoriasis. An unsupervised hierarchical clustering revealed a distinct cluster characterized by an expansion of T-helper 17 cells, T-regulatory cells, interleukin-17F, and interleukin-23. Conclusions: The current findings suggest that nonhematologic AIDs are prevalent in patients with CLL, and these patients have a better prognosis than patients who have AIC. The expansion of interleukin-17F-producing cells in patients with psoriasis may explain their good prognosis.
Ayudas:	Ministerio de Economía y Competitividad RD12/0036/0071 Instituto de Salud Carlos III PI19/00753
Derechos:	Aquest material està protegit per drets d'autor i/o drets afins. Podeu utilitzar aquest material en funció del que permet la legislació de drets d'autor i drets afins d'aplicació al vostre cas. Per a d'altres usos heu d'obtenir permís del(s) titular(s) de drets.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió acceptada per publicar
Materia:	Leukemia ; Lymphocytic ; Chronic ; Autoimmune diseases ; Th17 cells ; Interleukin 17 ; T lymphocytes ; Regulatory ; Prognosis ; Tumor microenvironment
Publicado en:	Cancer, Vol. 131, Num. 24 (December 2025) , art. e70216, ISSN 1097-0142

DOI: 10.1002/cncr.70216

Postprint 34 p, 3.2 MB

Disponible a partir de: 2026-12-31 Material complementari 27 p, 2.2 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados